Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby enclose copy of notice published in Economic Times (English) & Navshakti (Marathi) newspaper, on Wednesday, 21st December 2022 inviting attention of concerned shareholders to lodge their claims in respect of unclaimed dividends of the Company for last seven years, failing which their shares would be transferred to Investor Education and Protection Fund ('IEPF') account, in accordance with section 124(6) of the Companies Act, 2013 read with Rules.
21-12-2022
Bigul

AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, it is hereby informed that the management of the Company will be participating in a non-deal roadshow and will be meeting prospective investors as per schedule attached herewith.
25-11-2022
Bigul

AJANTA PHARMA LTD. - 532331 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Information on loss of share certificate
21-11-2022
Bigul

AJANTA PHARMA LTD. - 532331 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements), 2015

 Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of Related Party Transactions in the prescribed format for the half year ended 30th September 2022. Kindly take the same on your records.
14-11-2022
Bigul

AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

 Further to our communication dated 3rd November 2022 on earnings call, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, written transcript of the earnings call held on 3rd November 2022 at 5.00 p.m. has been uploaded on the Company's website and can be accessed through the link https://ajantapharma.com//images/EarningsCallTranscriptQ2FY23.pdf .
10-11-2022

Buy Ajanta Pharmaceuticals; target of Rs 1505: ICICI Direct

 ICICI Direct is bullish on Ajanta Pharmaceuticals recommended buy rating on the stock with a target price of Rs 1505 in its research report dated November 04, 2022.
07-11-2022
Bigul

AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to Regulation 47 of the Listing Regulations, please find enclosed copies of financial results of the Company for the second quarter and half year ended 30th September 2022 published in following newspapers on 4th November 2022: 1. Mumbai edition of Economic Times and 2. Mumbai edition of Maharashtra Times
04-11-2022
Bigul

AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 3rd November 2022 at 5.00 p.m. has been uploaded on the Company's website and can be accessed through the link: https://ajantapharma.com//images/EC-AudioQ2(Jul-Sep)2022-23.mp3
04-11-2022

Results Earnings Call for Q2FY23 of Ajanta Pharma

 Conference Call with Ajanta Pharma Management and Analysts on Q2FY23 Performance and Outlook. Listen to the full earnings transcript.
03-11-2022

This pharma stock to pay 350% dividend to shareholders, fixes record date

 Ajanta Pharma fixed November 14 as the record date for determining eligible shareholders, while the payment of the dividend will be done on or after November 24 this year.
03-11-2022
Next Page
Close

Let's Open Free Demat Account